Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

181. Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia

Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia Article Text Medical comorbidity Current use of second-generation

2013 Evidence-Based Mental Health

182. Cross-sectional study: In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life

Cross-sectional study: In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In individuals with schizophrenia, duration

2013 Evidence-Based Nursing

183. Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia

Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) technology-delivered support and education compared with standard care in people with schizophrenia Article Text Therapeutics Review: no clear benefit from information and communication technology-delivered support and education compared with standard care in people with schizophrenia Statistics from Altmetric.com Question Question: How effective are information and communication technologies (ICT) in delivering psychoeducational interventions to people with schizophrenia and related disorders? Outcomes

2013 Evidence-Based Mental Health

184. Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice

Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice Article Text Prognosis Atypical antipsychotics not associated with improved hospitalisation outcomes compared with typical antipsychotics in people with schizophrenia in real practice Statistics from Altmetric.com Question Question: What is the effectiveness and cost of atypical versus typical antipsychotic treatment in people with schizophrenia in real practice? Population: A total of 8610 adults (mean

2013 Evidence-Based Mental Health

185. Death rate in older people with schizophrenia elevated compared with the general population

Death rate in older people with schizophrenia elevated compared with the general population Death rate in older people with schizophrenia elevated compared with the general population | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Death rate in older people with schizophrenia elevated compared with the general population Article Text Prognosis Death rate in older people with schizophrenia elevated compared with the general population Statistics

2013 Evidence-Based Mental Health

186. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

187. Flupenthixol versus placebo for schizophrenia. (Abstract)

Flupenthixol versus placebo for schizophrenia. Flupenthixol, first made available in the UK in 1965, has been used as a treatment for schizophrenia for decades.To evaluate the absolute clinical effects of flupenthixol for schizophrenia in comparison with placebo.We searched the Cochrane Schizophrenia Group Trials Register (August 2011), inspected references of all included or excluded studies for further trials, and contacted authors of trials for additional information.All randomised (...) controlled trials (RCTs) that compared flupenthixol with placebo for adults with schizophrenia or related disorders by any means of diagnosis. Primary outcomes of interest were clinically important change in global state, mental state and behaviour, and adverse effects.We extracted data from the one included study, discussed any disagreement, documented decisions and contacted the authors of the included study for further information. We analysed binary outcomes using a standard estimation of the risk

2012 Cochrane

188. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia (Abstract)

Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia Some 25%–30% of patients with schizophrenia have auditory verbal hallucinations that are refractory to antipsychotic drugs. Outcomes in studies of repetitive transcranial magnetic stimulation suggest the possibility that application of transcranial direct-current stimulation (tDCS) with inhibitory stimulation over the left temporo-parietal cortex and excitatory stimulation over the left (...) dorsolateral prefrontal cortex could affect hallucinations and negative symptoms, respectively. The authors investigated the efficacy of tDCS in reducing the severity of auditory verbal hallucinations as well as negative symptoms.Thirty patients with schizophrenia and medication-refractory auditory verbal hallucinations were randomly allocated to receive 20 minutes of active 2-mA tDCS or sham stimulation twice a day on 5 consecutive weekdays. The anode was placed over the left dorsolateral prefrontal

2012 EvidenceUpdates Controlled trial quality: uncertain

189. Bitopertin for schizophrenia: primary, persistent negative symptoms sub-optimally controlled positive symptoms ? in combination with antipsychotics

Bitopertin for schizophrenia: primary, persistent negative symptoms sub-optimally controlled positive symptoms ? in combination with antipsychotics Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics NIHR HSC Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antipsychotic

2012 Health Technology Assessment (HTA) Database.

190. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Full Text available with Trip Pro

Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to assess the cost-effectiveness of olanzapine and ziprasidone in the treatment of schizophrenia in USA. The authors concluded that olanzapine was associated with better health outcomes

2012 NHS Economic Evaluation Database.

191. Asenapine - Schizophrenia

Asenapine - Schizophrenia Common Drug Review CDEC Meeting – May 16, 2012 Notice of CDEC Final Recommendation – June 14, 2012 Page 1 of 8 © 2012 CADTH CDEC FINAL RECOMMENDATION ASENAPINE (Saphris – Lundbeck Canada Inc.) Indications: Schizophrenia and Bipolar I Disorder Note: The Canadian Drug Expert Committee (CDEC) considered each of the two approved indications for asenapine separately. Schizophrenia Recommendation: The CDEC recommends that asenapine not be listed for the treatment (...) of schizophrenia. Reason for the Recommendation: In the eight double-blind randomized controlled trials (RCTs) reviewed by CDEC, asenapine failed to consistently demonstrate superiority in the five placebo-controlled trials; and in one of three trials comparing olanzapine with asenapine, olanzapine was superior to asenapine based on the primary outcome and a number of secondary outcomes. Thus, the key assumption of equivalent efficacy between asenapine and all comparators in the manufacturer’s economic

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

192. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Full Text available with Trip Pro

Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Schizophrenia is usually considered an illness of young adulthood. However, onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. At least 0.1% of the world's elderly population have a diagnosis of late-onset schizophrenia which seems to differ from earlier onset schizophrenia on a variety of counts including response to antipsychotic drugs.To assess the effects (...) of antipsychotic drugs for elderly people with late-onset schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (January 2010) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted relevant authors of trials for additional information.All relevant randomised controlled trials that compared antipsychotic drugs with other treatments for elderly people (at least 80% older than 65 years

2012 Cochrane

193. Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS) Full Text available with Trip Pro

Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS) Most people with schizophrenia in low- and middle-income (LAMI) countries receive minimal formal care, and there are high rates of non-adherence to medication.To evaluate the effectiveness of an intervention that involves a family member in supervising medication administration - supervised treatment in out-patients for schizophrenia (STOPS (...) ) - in improving treatment adherence and clinical outcomes.Individuals (n = 110) with schizophrenia or schizoaffective disorders were allocated to STOPS or to treatment as usual (TAU) and followed up for 1 year. The primary outcome was adherence to the treatment regimen. Positive and Negative Syndrome Scale for Schizophrenia and Global Assessment of Functioning scores were also assessed.Participants in the STOPS group had better adherence (complete adherence: 37 (67.3%) in STOPS v. 25 (45.5%) in TAU; P<0.02

2012 EvidenceUpdates Controlled trial quality: uncertain

194. Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia Full Text available with Trip Pro

Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia Phanthunane P, Vos T, Whiteford H, Bertram M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of interventions to treat schizophrenia, including typical antipsychotics, generic risperidone, olanzapine, clozapine, and family intervention. The authors concluded that atypical antipsychotics, such as risperidone, at generic prices, were cost-effective compared with typical antipsychotics, and family intervention was a cost-effective

2012 NHS Economic Evaluation Database.

195. Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials

Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

196. Use of benzodiazepines in adults with schizophrenia is associated with increased mortality

Use of benzodiazepines in adults with schizophrenia is associated with increased mortality Use of benzodiazepines in adults with schizophrenia is associated with increased mortality | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Use of benzodiazepines in adults with schizophrenia is associated with increased mortality Article Text Aetiology Use of benzodiazepines in adults with schizophrenia is associated with increased mortality Statistics

2012 Evidence-Based Mental Health

197. Review: maintenance antipsychotics prevent relapse in patients with schizophrenia

Review: maintenance antipsychotics prevent relapse in patients with schizophrenia Review: maintenance antipsychotics prevent relapse in patients with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: maintenance antipsychotics prevent relapse in patients with schizophrenia Article Text Therapeutics Review: maintenance antipsychotics prevent relapse in patients with schizophrenia Statistics from Altmetric.com

2012 Evidence-Based Mental Health

198. Review: emotion identification deficits are associated with functional impairments in people with schizophrenia

Review: emotion identification deficits are associated with functional impairments in people with schizophrenia Review: emotion identification deficits are associated with functional impairments in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: emotion identification deficits are associated with functional impairments in people with schizophrenia Article Text Prevalence Review: emotion identification

2012 Evidence-Based Mental Health

199. Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder Full Text available with Trip Pro

Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder Article Text Aetiology Atypical

2012 Evidence-Based Mental Health

200. Mortality risk in people with schizophrenia may vary according to class of antipsychotic used and concomitant medication

Mortality risk in people with schizophrenia may vary according to class of antipsychotic used and concomitant medication Mortality risk in people with schizophrenia may vary according to class of antipsychotic used and concomitant medication | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mortality risk in people with schizophrenia may vary according to class of antipsychotic used and concomitant medication Article Text Aetiology

2012 Evidence-Based Mental Health